Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOTAS-ELK-EB
NCT06713434Phase 1Active, not recruiting
- Sponsor
- Fundación DEBRA Chile
- Start
- May 2024
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ELK-003 in epidermolysis bullosa (EB), sponsored by Fundación DEBRA Chile. Primary endpoint: Safety of ELK-003 Eye Drops at 180 days. Started May 2024; status: active, not recruiting.
02
Drugs
ELK-003
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NCT06713434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06713434.